
<DOC>
<DOCNO>WT03-B24-201</DOCNO>
<DOCOLDNO>IA064-000380-B023-83</DOCOLDNO>
<DOCHDR>
http://www.sosei.com:80/BioCentury2/library/indstr/indstr.htm 206.86.52.80 19970112101905 text/html 4559
HTTP/1.0 200 OK
Date: Sun, 12 Jan 1997 10:19:09 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4377
Last-modified: Wed, 18 Sep 1996 23:39:00 GMT
</DOCHDR>

<HTML>
<BODY background = "../../graphics/white-mi.gif">
<HEAD><TITLE> Industry Structure</TITLE></HEAD>



<H1><center>Industry Structure</H1></center><P>

Each of the following abstracts is linked directly to the complete English-language article.<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/031196a1.htm"> Biotechology in Germany</A></B><br>
This article describes the emergence of biotechnology in Germany despite cultural and financial roadblocks. March 11, 1996 (4,200 words).<P>

<B><A HREF ="/BioCentury2/archive/1996/1qtr/010296a1.htm">1995 Was Successful for U.S. Biotech </A></B><BR>
The biotechnology sector emerged from a prolonged down period in 1995, reporting strong clinical data, obtaining product approvals, creating strong corporate partnerships, and raising $3.5 billion in the equity markets. This 
article discusses the factors underlying this upswing and considers the possibilities of continued improvement into 1996. Jan. 2, 1996 (3,600 words)

<B><A HREF ="/BioCentury2/archive/1995/4qtr/120495a1.htm"> Agricultural Biotechnology's Future </A></B><BR>
This article discusses the consolidation of U.S. agricultural biotechnology companies and considers the factors influencing future development of the sector. Dec. 4, 1995 (3,150 words)<P>

<B><A HREF="../../archive/1995/3qtr/0710a1.htm">Redefining the Biotech Industry</A></B><BR>

This Guest Commentary is by Mr. Stanley T. Crooke, Chairman and CEO of antisense pioneer Isis Pharmaceuticals Inc. Mr. Crooke discusses the future of the human therapeutic sector of biotechnology. He identifies five types of companies and their fundamentals for success. He proposes that biotechnology‰s long-term value be defined as enabling drug discovery platforms. 7.10.95 (3780 WORDS)<P>

Mr. Crooke wrote in response to Mr. Kenneth Ludlum of RiboGene Inc., who discusses the changing importance of technology in the evolution of several industrial sectors. See <A HREF="../../archive/1995/2qtr/0530a4.htm"> When Infatuation Ends</A> for Mr. Ludlum‰s Commentary. 30.5.95 (1580 WORDS)<P>


<B><A HREF="../../archive/1995/2qtr/0501a1.htm">Reality II</A></B><BR>

This Commentary about Centocor Inc.‰s ReoPro market introduction discusses the implications for biotechnology arising from economic decisions by U.S. hospitals about whether or not to add new drugs to their formularies. The challenge for biotechnology is how to create, price, and market new drugs in this frugal context, and even whether or not to begin new drug development. 1.5.95 (1700 WORDS)<P>

See <A HREF="../../archive/1995/2qtr/0424a1.htm">Reality I</A> for the first part of this Commentary.<P>

 
<B><A HREF="../../archive/1995/2qtr/0424a1.htm">Reality I</A></B><BR>

This story discusses the impact of cost control in the formulary decision at six hospitals about ReoPro, Centocor Inc.‰s anti-platelet antibody for use in high-risk angioplasty (2950 WORDS). An accompanying story discusses <A HREF="../../archive/1995/2qtr/0424a3.htm">ReoPro‰s Launch Program</A>. (475 WORDS) 24.4.95 <P>

See <A HREF="../../archive/1995/2qtr/0501a1.htm">Reality II</A> for the second part of this analysis.<P>


<B><A HREF="../../archive/1995/1qtr/0130a5.htm">Words of Wisdom</A></B><BR>

In this Commentary, Alejandro Zaffaroni, founder of Syntex, Alza Corp., DNAX Ltd., and Affymax N.V., describes hot areas in biotechnology and models for drug discovery. He advocates first studying receptors and proteins of interest, then developing products through the 'virtual' company. His ideas recognize the cost pressures, rate of scientific discovery, and suggest a way to return value to investors. 30.1.95 (800 WORDS)<P>

<h5><HR>

<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
<A HREF="http://www.sosei.com/"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/Graphics/home_button.gif">BioGlobe Home Page</A>
<A HREF="http://www.sosei.com/BioCentury2/homepg.htm"><IMG  Align=Middle Border =0
SRC="http://www.sosei.com/BioCentury2/graphics/bc_button.gif">BioCentury Home Page</A>

<HR>

Copyright (c) 1995 BioCentury Publications Inc. ALL RIGHTS RESERVED.<P>

BioCentury, The BioCentury 100 and The Clear Route to ROI are trade marks of BioCentury Publications Inc. All other trade marks are the property of their respective owners. </H5><P>



</BODY></HTML>




</DOC>